SCHEMBL2029894

SCHEMBL2029894

O=C1NC(=O)C(=Cc2cnn3c(NC4CC4)cc(NC(=O)c4ccccc4F)nc23)N1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 4/20 0.42
TYK2 P29597 6/20 0.38
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
CSNK2A2 P19784 3/20 0.36
CSNK2A1 P68400 1/20 0.36
KCNH2 Q12809 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HTR1A P08908 1/20 0.36
HTR1F P30939 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
GLA P06280 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029885 1.00 CSNK2B (0.42) CSNK2BTYK2LMNAPKMCSNK2A2
SCHEMBL12645979 0.94 CSNK2B (0.41) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL12644986 0.91 CSNK2B (0.42) CSNK2BTYK2LMNACSNK2A2CSNK2A1
SCHEMBL12645439 0.91 CSNK2B (0.41) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL12645446 0.91 CSNK2B (0.41) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL12645422 0.90 CSNK2B (0.42) CSNK2BTYK2LMNAPKMCSNK2A2
SCHEMBL12645980 0.90 CSNK2B (0.41) CSNK2BTYK2CSNK2A2CSNK2A1
SCHEMBL12645891 0.89 CSNK2B (0.40) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL12645420 0.88 CSNK2B (0.42) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL12645444 0.86 CSNK2B (0.42) CSNK2BTYK2PKMCSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2B 13/4885TYK2 63/4885LMNA 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.